VE-822 Berzosertib cas 1232416-25-9
| Product name:VE-822 Berzosertib | Purity:98% min |
| CAS NO:1232416-25-9 | Solubility:DMSO : ≥ 35 mg/mL (75.50 mM) |
| Molecular Formula:C24H25N5O3S | Package:Package according to customer requirements |
| Molecular Weight:463.552 | Storage:Store at -20℃ |
Berzosertib, also known as M6620, VE-822, VX-970, is an potent ATR inhibitor. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.
Related Prodcuts:
Fidaxomicin; Marbofloxacin; CP-466722; TTP 22; D-64131; M344; CHIR-124; Reversine; Pralatrexate; XL228; RI-1; SRPIN340; XL888; Rigosertib; APY29; NMS-873; PF-03758309; Telatinib
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.